Highlights Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-03-05 EST			5-day change	1st Jan Change
17.75 ^USD	-0.56%		-7.94%	-18.35%

02-23	Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion	RE
02-12	Legend Biotech Shares Lower After Rothschild & Co Redburn Downgrade	MT

Highlights

02-23	Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion	RE
12-08	Legend Biotech Corporation Highlights New CARVYKTI Data in Multiple Myeloma and First-In-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma	CI
11-13	Legend Biotech Corporation Celebrates Official Opening of New Cell Therapy Research and Development Facility in Philadelphia	CI
11-12	Legend Biotech Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-12	Legend Biotech Q3 Adjusted Loss Narrows, Revenue Rises	MT
11-12	Legend Biotech Q3 revenue slightly misses estimates	RE
11-12	Earnings Flash (LEGN) Legend Biotech Corporation Reports Q3 Revenue $272.3M, vs. FactSet Est of $274.4M	MT
11-12	Earnings Flash (LEGN) Legend Biotech Corporation Posts Q3 Adjusted Loss $0.05 per Share	MT
25-10-14	GenScript Associate Books $524 Million in Q3 CARVYKTI Sales	MT
25-10-14	Legend Biotech Corporation Announces U.S. Fda Approves Label Updates for Carvykti® Car-T Cell Therapy to Include Overall Survival Data	CI
25-10-13	The Presidential Whiplash Index
25-10-07	Legend Biotech USA Inc. Enters into Component and Product Supply Agreement with Janssen Pharmaceuticals, Inc	CI
25-09-05	Legend Biotech Said to Consider Second Listing Outside US	MT
25-09-05	Legend Biotech Said to Consider Second Listing Outside US, Bloomberg Reports	MT
25-08-11	Legend Biotech Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-11	Correction: Earnings Flash (LEGN) Legend Biotech Corporation Posts Q2 Adjusted EPS $0.03 per Share	MT
25-08-11	Legend Biotech Swings to Q2 Adjusted Earnings, Revenue Rises	MT
25-08-11	Legend Biotech Q2 collaboration revenue up on CARVYKTI sales	RE
25-08-11	Earnings Flash (LEGN) Legend Biotech Corporation Reports Q2 Revenue $255.1M, vs. FactSet Est of $228.0M	MT
25-08-11	Earnings Flash (LEGN) Legend Biotech Corporation Posts Q2 Loss $0.34 per Share, vs. FactSet Est of $-0.17	MT
25-06-30	Legend Biotech Provides Update on REMS for Currently Approves BCMA- and CD19-Directed Autologous Chimeric Antigen Receptor T Cell Immunotherapies	CI
25-06-27	US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies (June 27)	RE
25-06-03	Legend Biotech Corporation Unveils 5-Year Survival Data for Carvykti®? in Multiple Myeloma At 2025 Asco Annual Meeting	CI
25-05-23	Legend Biotech Corporation to Present New Data on Carvykti for Patients with Multiple Myeloma At 2025 Asco and Eha Annual Meeting	CI
25-05-22	Legend Biotech Corporation Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT	CI